CClinicalTrials.gg
Not yet recruitingNCT07684807ILECS-ECGPPGUpdated Jul 6, 2026

Synchronised ECG and PPG Data Collection for AI-based QT/QTc Reconstruction (ILECS-ECGPPG)

An observational study in Electrocardiography (ECG), Photoplethysmography and Healthy Volunteers, sponsored by Corsano Health B.V.. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Corsano Health B.V. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

This observational study will collect synchronized photoplethysmography (PPG) and electrocardiogram (ECG) recordings from approximately 50 healthy adult volunteers. Participants will wear the Corsano CardioWatch 297-2 and a reference ECG device simultaneously for approximately 24 hours, including standardized activities and free-lining conditions. The objective is to generate a high-quality paired ECG-PPG dataset to support the development and evaluation of artificial intelligence methods fro reconstructing ECG parameters, with a particular focus on QT/QTc, from PPG signals. The study will also evaluate the feasibility and usability of the wearable monitoring system.

Read the detailed description

Wearable devices have the potential to support continuous physiological monitoring in both clinical and home settings. Although photoplethysmography (PPG) enables comfortable long-term monitoring, it does not directly provide electrocardiographic (ECG) information. This study aims to establish a synchronized dataset of ECG and PPG recordings that can be used to develop and evaluate artificial intelligence algorithms for reconstructing ECG parameters, particularly QT/QTc, from PPG signals.

Approximately 50 healthy adult volunteers will be enrolled in this single-center, single-arm observational feasibility study. Participants will wear the Corsano CardioWatch 287-2 together with a reference continuous ECG device for approximately 24 hours. During the study, synchronized recordings will be collected during standardized activities (rest, standing, and light walking) as well as during normal daily activities.

The primary endpoints include completeness of paired ECG-PPG recordings, synchronization quality, and the proportion of recordings suitable for QT/QTc annotation. Secondary endpoints include participant comfort and usability of the wearable monitoring system, together with technical performance measures such as signal quality, device connectivity, and data completeness.

The resulting dataset will support future development and validation of AI-based methods for ECG parameter reconstruction from wearable PPG signals.

02

Conditions studied

  • Electrocardiography (ECG)
  • Photoplethysmography
  • Healthy Volunteers

Keywords

  • ECG
  • PPG
  • Wearable device
  • CardioWatch
  • Digital Health
03

In context

Lead sponsor

Corsano Health B.V. is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy adult volunteers, including hospital employees, recruited at a single clinical site.

Inclusion criteria

  • Able to provide written informed consent.
  • Willing and able to comply with all study procedures and attend the required study visits.
  • Age ≥18 years.
  • Able to read or understand Dutch or English.

Exclusion criteria

Exclusion Criteria:

  • Children/minors or vulnerable individuals.
  • Skin conditions or allergies preventing safe wear of the CardioWatch or ECG electrodes.
  • Any condition that, in the investigator's opinion, may interfere with study completion or data quality.
  • Compromised circulation, injury, or physical malformation at sensor sites.
  • Known clotting disorders or current prescription anticoagulant therapy.
  • Other health conditions preventing safe participation.
  • Wrist circumference \<14 cm or >23 cm.
  • Any participant who, in the investigator's opinion, does not meet study requirements
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy adult volunteers

    Approximately 50 healthy adult volunteers who will wear the Corsano CardioWatch 287-2 and a reference ECG device simultaneously for approximately 24 hours, including standardized activities and free-living monitoring, to collect synchronized ECG and PPG recordings

    Device: Corsano CardioWatch 287-2 · Device: VivaLNK wearable ECG patch

Interventions

  • DeviceCorsano CardioWatch 287-2

    Wrist-worn wearable device used to collect continuous photoplethysmography (PPG) signals and related physiological data during the study. The device is used simultaneously with a reference ECG device to generate synchronized ECG-PPG datasets for AI algorithm development and evaluation.

  • DeviceVivaLNK wearable ECG patch

    Continuous reference ECG device used as the gold standard for synchronized ECG recordings and QT/QTc reference annotation

06

What researchers measure

Primary outcomes

  1. Completeness of paired recordings, synchronisation quality (offset/drift indicators), and proportion of usable segments for QT/QTc reference annotation

    Assessment of paired ECG-PPG recording completeness, synchronization quality using offset and drift indicators, and the proportion of usable segments for QT/QTc reference annotation

    Time frame: 24 hours

Secondary outcomes

  1. Usability/comfort of Corsano CardioWatch 287-2 (questionnaire) and technical issue rates (e.g., sensor detachment, connectivity interruptions)

    Assessment of participant-reported usability and comfort of the Corsano CardioWatch 287-2 using a questionnaire, together with the frequency and type of technical issues affecting data collection, including sensor detachment, connectivity interruptions, and other technical problems encountered during the study

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07684807
Lead sponsor
Corsano Health B.V.
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jul 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jul 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion